|
Cytokinetics to Present at the RBC Capital Markets Healthcare Conference
(Marketwire Via Acquire Media NewsEdge) SOUTH SAN FRANCISCO, CA, December 3 / MARKET WIRE/ --
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Sharon Barbari, Senior Vice President, Finance
and Chief Financial Officer, is scheduled to participate in a panel
discussion entitled "Replacing The Mainstay With Newer And Better Agents"
at the RBC Capital Markets 2008 Healthcare Conference on Wednesday,
December 10, 2008 at 4:30 p.m. Eastern Time at The Westin Times Square
Hotel in New York, New York.
Interested parties may access the live audio webcast of these presentations
and replays by visiting the Investors Relations section of the Cytokinetics
website at www.cytokinetics.com. The webcast replay of the presentation
will be archived on the Presentations page within the Investors Relations
section of Cytokinetics' website for two weeks following the completion of
each of the events.
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on the discovery,
development and commercialization of novel small molecule drugs that may
address areas of significant unmet clinical needs. Cytokinetics'
cardiovascular disease program is focused to cardiac myosin, a motor
protein essential to cardiac muscle contraction. Cytokinetics' lead
compound from this program, CK-1827452, a novel small molecule cardiac
myosin activator, entered Phase II clinical trials for the treatment of
heart failure in 2007. Under a strategic alliance established in 2006,
Cytokinetics and Amgen Inc. are performing joint research focused on
identifying and characterizing activators of cardiac myosin as back-up and
follow-on potential drug candidates to CK-1827452. Amgen has obtained an
option for an exclusive license to develop and commercialize CK-1827452,
subject to Cytokinetics' development and commercial participation rights.
Cytokinetics' cancer program is focused on mitotic kinesins, a family of
motor proteins essential to cell division. Under a strategic alliance
established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting
research and development activities focused on the potential treatment of
cancer. Cytokinetics is developing two novel drug candidates that have
arisen from this program, ispinesib and SB-743921, each a novel inhibitor
of kinesin spindle protein (KSP), a mitotic kinesin. Cytokinetics is
conducting the Phase I portion of a Phase I/II clinical trial of ispinesib
as monotherapy as a first-line treatment in chemotherapy-na?ve patients
with locally advanced or metastatic breast cancer. In addition,
Cytokinetics is conducting the Phase I portion of a Phase I/II trial of
SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma. GSK has an
option for the joint development and commercialization of ispinesib and
SB-743921. GSK-923295, a CENP-E inhibitor, is being developed under the
strategic alliance by GSK; GSK began a Phase I clinical trial with
GSK-923295 in 2007. In April 2008, Cytokinetics announced the selection of
a potential drug candidate directed towards skeletal muscle contractility
which may be developed as a potential treatment for skeletal muscle
weakness associated with neuromuscular diseases or other conditions. All of
these drug candidates and potential drug candidates have arisen from
Cytokinetics' research activities and are directed towards the
cytoskeleton. The cytoskeleton is a complex biological infrastructure that
plays a fundamental role within every human cell. Additional information
about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements relating to
Cytokinetics' and its partners' research and development activities, future
presentations concerning Cytokinetics' research and development programs,
the potential benefits of Cytokinetics' drug candidates and potential drug
candidates and the enabling capabilities of Cytokinetics' cytoskeletal
focus. Such statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential difficulties or
delays in the development, testing, regulatory approval, production and
marketing of Cytokinetics' drug candidates that could slow or prevent
clinical development, product approval or market acceptance, including
risks that current and past results of clinical trials or preclinical
studies may not be indicative of future clinical trials result; patient
enrollment for clinical trials may be difficult or take longer than
anticipated; Cytokinetics' drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy, the U.S. Food and Drug
Administration or foreign regulatory agencies may delay or limit
Cytokinetics' or its partners' ability to conduct clinical trial;
Cytokinetics may be unable to obtain and maintain patent or trade secret
protection for its intellectual property; potential decisions by GSK to
postpone or discontinue development efforts for GSK-923295 or not exercise
its options to ispinesib or
SB-743921; Cytokinetics may incur unanticipated research and development
and other costs or be unable to obtain additional financing if necessary;
standards of care may change rendering our products; others may introduce
products or alternative therapies for the treatment of the indications that
Cytokinetics' drug candidates and potential drug candidates currently or
potentially may target; and risks and uncertainties relating to the timing
and receipt of funds under Cytokinetics' collaborations. For further
information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the
Securities and Exchange Commission.
Contact:
Christopher S. Keenan
Director, Investor Relations
(650) 624-3000
Copyright ? 2008 Marketwire
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
